Relevant bibliographies by topics / Potential Drug – Drug Interactions

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Potential Drug – Drug Interactions'

Author: Grafiati
Published: 4 June 2025
Last updated: 23 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Potential Drug – Drug Interactions.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Potential Drug – Drug Interactions"

1

Fernández de Palencia Espinosa, Ma Ángeles, Ma Sacramento Díaz Carrasco, Andrés Sánchez Salinas, Amelia de la Rubia Nieto, and Alberto Espuny Miró. "Potential drug–drug interactions in hospitalised haematological patients." Journal of Oncology Pharmacy Practice 23, no. 6 (2016): 443–53. http://dx.doi.org/10.1177/1078155216664201.

Full text
Abstract:
Background Frequently, haematological patients undergo highly complex and intensive treatment protocols, so a high risk of drug–drug interactions could be expected. Objectives To determine prevalence of clinically relevant drug–drug interactions, to identify the most frequent drug–drug interactions and associated risk factors. Methods A prospective, observational and descriptive study was carried out from November 2012 to February 2013. Twice a week, every patient’s treatment sheet was collected. Each medication list was screened through two databases: Thomson MicromedexTM and Drug Interaction FactsTM. All identified potential drug–drug interactions with a moderate or higher severity rating were recorded. Summary statistics were used to describe patient and disease characteristics, most often prescribed drugs, and frequency, types and classification of drug–drug interactions. Multiple logistic regression models were used to identify risk factors associated with drug–drug interactions. Results A total of 2061 drug–drug interactions were detected in 317 treatment sheets from 58 patients. The prevalence of treatment sheets with drug–drug interactions by Micromedex and Drug Interaction Facts databases were 74.1% and 56.8%, respectively. Azole antifungals, immunosuppressive drugs, antiemetics, antidepressants, acid suppressants and corticosteroids were the most frequent involved drugs. In multivariate analysis, the main risk factor associated with increased odds for drug–drug interactions was a higher number of non-antineoplastic drugs. Conclusions The prevalence of drug–drug interactions was common, with immunosuppressant and azole antifungal agents being the most commonly involved drugs. The factor having the greatest influence on drug–drug interactions was a higher number of non-antineoplastic drugs.
APA, Harvard, Vancouver, ISO, and other styles
2

Isnenia, Isnenia. "Penggunaan Non-Steroid Antiinflamatory Drug dan Potensi Interaksi Obatnya Pada Pasien Muskuloskeletal." Pharmaceutical Journal of Indonesia 6, no. 1 (2020): 47–55. http://dx.doi.org/10.21776/ub.pji.2020.006.01.8.

Full text
Abstract:
The main therapy on musculoskeletal patients is the use of non-steroidal anti-inflammatory drugs (NSAIDs) either as monotherapy or in combination with drugs of the same class or pain relievers from other groups. The use of more than one drugs have potentially caused drug-drug interactions that can affect to patient. This study was aimed to describe the patient's sociodemographic (sex, ages) and clinical (numbers of drugs, type of drugs and diagnose) characteristics, as well as to find the correlation between potential drug interactions with these variables. This research was a quantitative study with a cross sectional design. Data were taken from 100 medical records of patients who had diagnosed with top five musculoskeletal diseases. Data were analyzed descriptively for sex, ages, number of drugs, type of drugs, and potential drug interactions. Bivariate correlation with chi-square were conducted to find statistically significancy potential drug interactions with each variable consist of sex, ages, type of drugs and it’s diagnose. The result shows that the musculoskeletal patients were 44% male, 56% female. Most musculoskeletal patients were aged 18-65 years (78%). Patients who received drugs <5 were 68% and ≥ 5 were 32%. 54% of patients were taking the diclofenac and only 5% of patients were taking the two NSAIDs combination, diclofenac and ibuprofen. There was no significant correlation (p > 0,05) between potential drug interactions with age, sex, type of NSAID, and type of musculosceletal diseases.
APA, Harvard, Vancouver, ISO, and other styles
3

Ceylan, Cengizhan, Rashida Muhammad Umar, Büşra Nur Çattık, Fatih Bolel, Mert Şahna, and Emine Karataş Koçberber. "Potential Drug-Drug Interactions in Patients Using Warfarin, Heparin, and Enoxaparin." Avicenna Journal of Pharmaceutical Research 2, no. 2 (2021): 60–65. http://dx.doi.org/10.34172/ajpr.2021.12.

Full text
Abstract:
Background: Drug-drug interactions can often lead to preventable adverse drug events and hospitalization. However, the clinical outcome of a potential drug-drug interaction that may range from minor alterations to major toxicity or loss of effect is often unknown. Drugs with narrow therapeutic index are more susceptible to the outcomes of interactions. Anticoagulants are one of the drug groups prone to drug-drug interactions and have important side effects. in this retrospective study, the frequency of drug-drug interactions involving warfarin, heparin and enoxaparin was investigated. Methods: Overall, 300 patients (including 55% males with an average age of 50.75 years) participated in this study, and for each anticoagulant, 100 patient orders were randomly selected from the hospital system. Drug-drug interactions were evaluated using the Micromedex drug interaction checker. Results: A total of 1691 drug-drug interactions (306 major, 253 moderate, and 89 minor interactions) were recorded of which only 648 (average 2.16) involved warfarin, heparin, or enoxaparin. Most interactions were recorded in patients admitted to the cardiovascular surgery (n=312) and cardiology (n=119) wards. There was a significant relationship between the number of drugs and the frequency of interaction. warfarin had the highest number of interactions (n=388). Conclusion: The frequency of drug interactions is high in patients on anticoagulant therapy. The efficacy and safety of these drugs can be affected by drug interactions. Accordingly, these interactions should always be considered, especially in patients with multiple drug use. Efficient monitoring strategies should be employed to optimize treatment while reducing adverse effects.
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Maraviroc potential drug-drug interactions." Reactions Weekly &NA;, no. 1207 (2008): 5. http://dx.doi.org/10.2165/00128415-200812070-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Božić-Cvijan, Bojana, Miljana Labović, Marija Kukurić, and Milica Bajčetić. "Drug-drug interactions of the reserve antibiotics: A narrative review." Medicinska istrazivanja 57, no. 2 (2024): 149–61. http://dx.doi.org/10.5937/medi57-49267.

Full text
Abstract:
Drug interactions often cause side effects, especially in children, elderly and/or patients with chronic diseases. Antibiotics are among the most commonly used drugs, so potential impact of antibiotic-drug interactions on the ultimate outcome of therapy may be of great clinical value. Bearing in mind that antibiotic-drug interactions can lead to development of antimicrobial resistance (AMR), their identification is specifically important for reserve antibiotics. The aim of this narrative review is to analyze the drug-drug interaction potential of reserve antibiotics. The highest potential for antibiotic-drug interactions was identified with linezolid, colistin, dalfopristin/quinupristin, lefamulin and oritavancin. Special caution should be paid to concomitant administration of ceftazidime-avibactam, telavancin, colistin, polymyxin B, plazomicin with drugs that have nephrotoxic potential due to possibility of more severe renal impairment. Exceptional wariness is required when combining drugs with reserve antibiotics with limited drug-drug interactions information such as plazomicin, carumonam, iclaprim. Having in mind that antibiotic-drug interaction can lead to the changed antimicrobial efficiency and/or safety of the therapy, the antibiotic choice has to be based on data regarding interaction potential. Continuous education of clinical staff regarding the choice of antibiotics based on their interaction potential and optimizing the antibiotic dose may significantly improve pharmacotherapy and decrease the risk for AMR.
APA, Harvard, Vancouver, ISO, and other styles
6

Vecchia, Stefano, Elena Orlandi, Corrado Confalonieri, et al. "Prevalence study on potential drug–drug interaction in cancer patients in Piacenza hospital’s Onco-Haematology department." Journal of Oncology Pharmacy Practice 24, no. 7 (2017): 490–93. http://dx.doi.org/10.1177/1078155217717324.

Full text
Abstract:
Background Cancer patients can be a human model of potential drug interactions. Usually they receive a large number of different medications, including antineoplastic agents, drugs for comorbid illness and medication for supportive care, however information about these interactions are fragmented and poor. Objective We assessed a prospective study to evaluate the prevalence of drug interaction among patients hospitalized in the Onco-Haematology department, Hospital of Piacenza. Methods Data on drugs administered for cancer, comorbidities, or supportive care were collected from different computerized prescription software in use in the department; we compared them with a database to focus on the co-administration of drugs. A literature review was performed to identify major potential drug interaction and to classify them by level of severity and by strengths of scientific evidence. Results In this study 284 cancer patients were enrolled; patients had taken an average of seven drugs on each day of therapy plus chemotherapeutic agents, we identified 67 potential drug interactions. At least 53 patients had one potential drug interaction. Of all potential drug interactions 63 were classified as moderate severity and only four as major. In 55 cases chemotherapeutic agents were involved in possible interactions with supportive care drugs, meanwhile in 12 cases the potential drug interactions were between supportive care drugs. Conclusions In our centre, thanks to a computerized prescription software, integrated with caution alarm in case of possible interaction, we had a lower rate of potential drug interactions than the one from literature. It is possible to improve the software integrating the alarm with the potential drug interactions between chemotherapy agents and supportive care drugs.
APA, Harvard, Vancouver, ISO, and other styles
7

Dickson, Michael, Thomas J. Bramley, Chris Kozma, Dilesh Doshi, and Marcia F. T. Rupnow. "Potential drug–drug interactions with antiepileptic drugs in Medicaid recipients." American Journal of Health-System Pharmacy 65, no. 18 (2008): 1720–26. http://dx.doi.org/10.2146/ajhp070508.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sahasrabudhe, Vaishali, Tong Zhu, Alfin Vaz, and Susanna Tse. "Drug Metabolism and Drug Interactions: Potential Application to Antituberculosis Drugs." Journal of Infectious Diseases 211, suppl 3 (2015): S107—S114. http://dx.doi.org/10.1093/infdis/jiv009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Thomas, L., S. J. Kurian, N. Mukherjee, et al. "Potential drug–drug interactions among hospitalised TB patients." International Journal of Tuberculosis and Lung Disease 26, no. 12 (2022): 1137–43. http://dx.doi.org/10.5588/ijtld.22.0107.

Full text
Abstract:
BACKGROUND: Hospitalised TB patients are at heightened risk for developing drug–drug interactions (DDIs) due to overlapping CYP450 enzyme and/or drug transporter biotransformation of anti-TB drugs and co-medications given for treating TB-associated comorbidities. We aimed to compare the occurrence, characterisation and determinants of database identified potential DDIs (pDDIs) associated with first-line anti-TB drugs and other co-medications using a subscription and free access drug information database.METHOD: This was a single-centre retrospective study to assess pDDIs between first-line anti-TB drugs and other medications for comorbidities among hospitalised TB patients using IBM Micromedex® and Drugs.com.RESULTS: On multivariate regression analysis, hospitalised TB patients with comorbidities such as diabetes mellitus, HIV infection and hypertension, longer hospitalisation, and patients administered with more than seven drugs during their hospital stay were associated with increased risk for the occurrence of pDDIs. Significant discrepancies were observed in the detection and severity of pDDIs between IBM Micromedex and Drugs.com.CONCLUSION: We recommend using free access drug information database to a subscription drug information database in drug interaction screening protocols in clinics for enhanced identification of pDDIs and reducing monetary burden in resource-limited settings.
APA, Harvard, Vancouver, ISO, and other styles
10

HamaSalih, Raz Muhammed, Rebwar Ghareeb Hama, Sabir Hamid, Pavel Jalal Hussein, and Sham Nawshirwan Salh. "Prevalence of Potential Drug-drug Interactions among Psychiatric Patients at Psychiatry Hospital in Sulaimani City." Al Mustansiriyah Journal of Pharmaceutical Sciences 24, no. 4 (2024): 422–34. http://dx.doi.org/10.32947/ajps.v24i4.1090.

Full text
Abstract:
Background: Clinically significant drug-drug interactions can be defined as events in which the pharmacodynamics or pharmacokinetic characteristics of a drug are modified by coadministration of a second drug to the patient’s medication protocol, which can often lead to in an increase of serious adverse reactions. The probability of interactions increases with higher number of drugs administered. Objective: The objective of this prospective study was to determine the prevalence of potential psychotropic drug-drug interactions among hospitalized patients at Psychiatry hospital in Sulaimani city, and to identify the clinical consequence of such combinations. Method: The current study was involved recruiting the data regarding prescribed psychotropic drugs of 60 newly hospitalized psychiatric patients. Data collection on each individual patient was performed on the specific patient dossier of to report any potential psychotropic drug-drug interactions utilizing Medscape drug interaction checker for identification of the different types of drug-drug interactions. Result: The prevalence of potential drug-drug interaction at Psychiatry Unit in Sulaimani city in 60 patients was 98%, of which 16.6% were major drug-drug interactions. The most frequently prescribed medications were antidepressant drugs, most of patients received more than four drugs. Conclusion: From the current study one can conclude that there was a high prevalence of potential drug-drug interactions among psychiatric patients, which was more frequent in patients taking more than one psychotropic medication.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Potential Drug – Drug Interactions"

1

Reimche, Leanne D. "Potential drug-drug interactions in a Canadian tertiary-care hospital." Thesis, University of Ottawa (Canada), 2008. http://hdl.handle.net/10393/27724.

Full text
Abstract:
Drug-Drug interactions (DDIs) are an important focus of patient safety because they account for a substantial number of adverse drug events and are preventable. Objective. To study DDIs in a Canadian hospital, a retrospective observational study was completed using the Ottawa Hospital Data Warehouse. Study cohort. Admissions to the Ottawa hospital between January 1, 1999 and September 30, 2005. Methods. Potential drug-drug interactions were identified by examining all co-administered medications for combinations of drugs previously reported to have potential interactions. Poisson regression was used to examine potential patient and hospital factors associated with drug-drug interactions. Results. Between 1999 and 2005, we found at least one DDI in 19.3% of all hospitalizations and 18.8% of hospitalization time. Category 1 (drug combinations to be avoided) and Category 2 (drug combinations usually avoided) interactions were rare, accounting for only 0.022% and 1.4% of hospitalization time, respectively. Category 3 interactions (drug combinations requiring alteration) occurred with 5.7% of all drug orders and were present for 17.4% of hospitalization time. Poisson regression analysis found that DDIs were significantly more likely to occur in patients who were: older; admitted to a surgical service; had a greater number of comorbidities; and were prescribed a greater number of drugs. Conclusion. Drug-Drug interactions occurred frequently during hospitalization. Future study is required to determine if the interactions identified are associated with important clinical outcomes.
APA, Harvard, Vancouver, ISO, and other styles
2

Sánchez, Pascua Teresa. "Carboxylesterase 1 genetic variability, expression and potential for drug-drug interactions." Thesis, University of Liverpool, 2014. http://livrepository.liverpool.ac.uk/2006752/.

Full text
Abstract:
Carboxylesterase 1 (CES1) is the main human liver esterase and is involved in the metabolism and disposition of numerous endogenous and pharmacological compounds. Some of the substrates of this enzyme are widely prescribed agents such as clopidogrel (Plavix®), methylphenidate (Ritalin®) and oseltamivir (Tamiflu®). However, there is much uncertainty regarding the genetic variability within CES1, and its regulation and involvement in drug-drug interactions (DDI). Polypharmacy is frequent in elderly, HIV and tuberculosis infected populations, and the risk of harmful DDIs is high, especially when these populations overlap. The role played by CES1 on the treatment of all these three pathologies and vice versa needs to be better characterized. In this thesis the role of CES1 genetic variability and its potential role in DDIs are explored both in isolation and in conjunction with other genetic, demographic, physio-pathological and iatrogenic factors. The impact of CES1 genetic variability was assessed on the anti-platelet effect of clopidogrel as well as on isoniazid pharmacokinetics in acute coronary syndrome (ACS) and HIV/Tuberculosis co-infected populations respectively. DDIs mediated by CES1 were explored in a HIV positive cohort treated with clopidogrel and non-nucleoside reverse transcriptase inhibitors (NNRTIs). Also, in vitro experiments with primary hepatocytes were used to investigate CES1 intracellular expression in the presence of prototypical PXR inducers used in tuberculosis treatment. The results of this thesis show that the CES1 rs2244613 SNP does affect clopidogrel anti-aggregant activity and may contribute to treatment non-response. Another CES1 variant, rs3815583, was found to be associated with changes in isoniazid pharmacokinetics. The studies did not indicate that NNRTI coadministration with clopidogrel would impair the anti-platelet activity since no relevant changes in exposure of the antiplatelet agent were identified. In the same way, the results do not anticipate DDIs between CES1 substrates and rifamycins, since no induction of expression was identified after incubating primary human hepatocytes in vitro with rifampicin, rifabutin and rifapentine. In conclusion, the results shown in this thesis support the idea that CES1 genetic variability may play a bigger role than previously suspected in treatment response but may not be a mediator of clinically relevant DDIs.
APA, Harvard, Vancouver, ISO, and other styles
3

Scott, Rebecca Jane. "An in vivo cytochrome P450 probe cocktail approach to identify potential drug-drug interactions." Thesis, King's College London (University of London), 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.407189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ventura, Ventanachs Verònica. "In vitro metabolism and drug-drug interaction potential of irosustat, a steroidal sulfatase inhibitor." Doctoral thesis, Universitat de Barcelona, 2013. http://hdl.handle.net/10803/124483.

Full text
Abstract:
Irosustat is a first-generation, irreversible, steroid sulfatase inhibitor currently in development for hormone-dependent cancer therapy. Its structure is a tricyclic coumarin-based sulfamate that undergoes desulfamoylation in aqueous solution, yielding the sulfamoyl-free derivative, 667-coumarin. The first aim of the present work was to study the in vitro metabolism of irosustat, including its metabolic profile in liver microsomes and hepatocytes, the potential species differences, and the identification of the main metabolites. And the second aim of the present work was to predict potential drug-drug interactions between irosustat and possible concomitantly administered medications through the investigation in vitro of the enzymes participating in the metabolism of irosustat and its inhibition/induction potential with the main drug-metabolizing enzymes. The interaction of aromatase inhibitors in the in vitro metabolism of irosustat was also studied. Irosustat was extensively metabolized in vitro, showing similar metabolite profiles among rat, dog, monkey, and humans (both sexes). In liver microsomes, the dog was the species that metabolized irosustat most similarly to metabolism in humans. Marked differences were found between liver microsomes and hepatocytes, meaning that phase I and phase II enzymes contribute to irosustat metabolism. Various monohydroxylated metabolites of irosustat and of 667-coumarin were found in liver microsomes, which mostly involved hydroxylations at the C8, C10, and C12 positions in the cycloheptane ring moiety. 667-Coumarin was formed by degradation but also by non-NADPH-dependent enzymatic hydrolysis, probably catalyzed by microsomal steroid sulfatase. The main metabolites formed by hepatocytes were glucuronide and sulfate conjugates of 667-coumarin and of some of its monohydroxylated metabolites. The major cytochrome P450 enzymes involved in the transformation of irosustat were CYP2C8, CYP2C9, CYP3A4/5, and CYP2E1. Moreover, various phase II enzymes (UDP-glucuronosyltransferases and sulfotransferases) were capable of conjugating many of the metabolites of irosustat and 667-coumarin; however, the clinically relevant isoforms could not be elucidated. Irosustat inhibited CYP1A2 activity in human liver microsomes through the formation of its desulfamoylated degradation product and metabolite 667-coumarin. CYP1A2 inhibition by 667-coumarin was competitive, with a K(i) of 0.77 μM, a concentration exceeding by only 5-fold the maximal steady-state concentration of 667-coumarin in human plasma with the recommended dose of irosustat. In addition, 667-coumarin metabolites enhanced the inhibition of CYP1A2 activity. Additional clinical interaction studies of irosustat with CYP1A2 substrate drugs are strongly recommended. 667-Coumarin also appeared to be a competitive inhibitor of CYP2C19 (K(i) = 5.8 μM) in human liver microsomes, and this inhibition increased with assessment in human hepatocytes. Inhibition of CYP2C19 enzyme activity was not caused by repression of CYP2C19 gene expression. Therefore, additional mechanistic experiments or follow-up studies with clinical evaluation are recommended. Irosustat neither inhibited CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4/5, or UDP-glucuronosyltransferase 1A1, 1A4, or 2B7 activities nor induced CYP1A2, CYP2C9, CYP2C19, or CYP3A4/5 at clinically relevant concentrations. Results from human liver microsomes indicated that no changes in irosustat pharmacokinetics in vivo are expected as a result of inhibition of irosustat metabolism in cases of concomitant medication administration or irosustat-aromatase inhibitor combination therapy with letrozole, anastrozole, or exemestane.<br>Irosustat és un inhibidor irreversible de la sulfatasa esteroidal, de primera generació, actualment en desenvolupament per al tractament del càncer dependent d'hormones. Els objectius d'aquest treball van ser estudiar el metabolisme in vitro d'irosustat, incloent el seu perfil metabòlic en microsomes hepàtics i hepatòcits, les diferències entre espècies, així com la identificació dels principals metabòlits. I també predir les possibles interaccions fàrmac-fàrmac entre irosustat i possibles medicaments administrats de forma concomitant, a través de la investigació in vitro dels enzims que participen en el metabolisme de irosustat i el seu potencial d'inhibició / inducció dels principals enzims metabolitzants de fàrmacs. La interacció dels inhibidors de l'aromatasa en el metabolisme in vitro del irosustat també es va estudiar. Irosustat és extensament metabolitzat in vitro, mostrant perfils metabòlics similars entre rates, gossos, micos i humans (ambdós sexes). En microsomes de fetge, el gos va ser l'espècie que metabolitza irosustat de forma més similar al metabolisme en humans. 667-coumarin es va formar per degradació, però també per hidròlisi enzimàtica no dependent de NADPH, probablement catalitzada per la sulfatasa esteroidal microsomal. Es van trobar grans diferències entre els perfils metabòlics de microsomes hepàtics i de hepatòcits, significant que tant enzims de fase I com de fase II contribueixen al metabolisme del irosustat. Els principals metabòlits formats pels microsomes de fetge van ser monohidroxilats del irosustat i de la 667-coumarin, mentres que en hepatòcits van ser conjugats glucurònids i sulfats de 667-coumarin i d'alguns dels seus metabòlits monohidroxilats. Els principals enzims del citocrom P450 involucrats en la transformació del irosustat van ser CYP2C8, CYP2C9, CYP3A4/5, i CYP2E1. D'altra banda, diversos enzims de fase II (UDP-glucuronosiltransferasas i sulfotransferasas) eren capaços de conjugar molts dels metabòlits de irosustat i 667-coumarin, però, les isoformes clínicament rellevants no es van poden dilucidar. Irosustat inhibeix les activitats dels CYP1A2 i CYP2C19 en microsomes de fetge humà a través de la formació de 667-coumarin. Es recomanen estudis clínics addicionals d'interacció entre irosustat i substrats del CYP1A2. Pel CYP2C19, aquesta inhibició va augmentar amb l'avaluació en hepatòcits humans, tot i que no va ser causada per la repressió de l'expressió del gen CYP2C19. Per tant, es recomanen experiments mecanistics addicionals o estudis de seguiment amb avaluació clínica. Irosustat no inhibeix CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4/5, UGT1A1, UGT1A4 ni UGT2B7. Tampoc indueix CYP1A2, CYP2C9, CYP2C19 o CYP3A4/5, a concentracions clínicament rellevants. Els resultats dels microsomes hepàtics humans van indicar que no s'espera canvis en la farmacocinètica del irosustat com a resultat de la inhibició del seu metabolisme en els casos d'administració concomitant d’inhibidors de l’aromatase: letrozole, anastrozole, o exemestane.
APA, Harvard, Vancouver, ISO, and other styles
5

Song, Mi Chi, and Austin Gessay. "Medical, Nursing, and Pharmacy Students’ Ability to Recognize Potential Drug-Drug Interactions: A Comparison of Healthcare Professional Students." The University of Arizona, 2009. http://hdl.handle.net/10150/623967.

Full text
Abstract:
Class of 2009 Abstract<br>OBJECTIVES: The purpose of this study is to evaluate and compare the DDI knowledge of pharmacy, medical, and nurse practitioner students who are beginning clinical clerkships. METHODS: This study utilized a prospective evaluation of DDI knowledge among healthcare professional students who were currently enrolled in their final didactic year at the University of Arizona College of Medicine, College of Pharmacy, or College of Nursing’s nurse practitioner course. Students were provided with 15 possible DDI pairs, and asked to select an appropriate management strategy for each pair. Management options included: “Avoid Combination,” “Usually Avoid Combination,” “Take Precaution,” “No Special Precaution,” and “Not Sure.” The primary outcome measure was the ability to correctly categorize each DDI pair into one of the five management responses. The secondary outcome measure was the number of clinically significant DDIs recognized. Analysis of variance was used to evaluate differences between groups. An alpha of 0.05 was set a-priori. RESULTS: Response rates were 61% for medical students (72 of 119), 82% for pharmacy students (64 of 78) and 100% for nurse practitioner students (29 of 29). The mean number correct for management strategies was comparable in the medical students (2.5, SD= 1.9) and nurse practitioner students (3.0, SD= 1.9), while the pharmacy students had a mean score of 6.1 (SD= 2.2) correct answers. There was a significant difference between the groups in correct responses (p< 0.001). In regards to student ability to identify interactions, the mean number correct was 10.1 (SD= 2.6), 5.0 (SD= 3.3), and 4.4 (SD= 3.0) for pharmacy, medicine, and nursing respectively (F= 60.6; p< 0.001). Post hoc analysis demonstrated that pharmacy students performed significantly better than medical and nurse practitioner students in regards to their ability to: 1) select management strategies for DDI pairs; and 2) identify a DDI interaction. No significant differences were found between the medical and nurse practitioner students. CONCLUSIONS: Pharmacy students demonstrated better knowledge than medical and nurse practitioner students with respect to identifying and selecting management strategies for possible DDIs. However, there is much room for improvement for all groups.
APA, Harvard, Vancouver, ISO, and other styles
6

Sepcic, Kelly Hall. "Sythesis of mazindol derivatives as potential irreversible antagonists of cocaine and other stimulants." Thesis, Georgia Institute of Technology, 1992. http://hdl.handle.net/1853/26819.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

au, low@wehi edu, and CK Andrew Low. "Characterisation and Evaluation of Novel Potential Target (Tubulin) for Antimalarial Chemotherapy." Murdoch University, 2004. http://wwwlib.murdoch.edu.au/adt/browse/view/adt-MU20050930.125714.

Full text
Abstract:
Malaria has long affected the world both socially and economically. Annually, there are 1.5-2.7 million deaths and 300-500 million clinical infections (WHO, 1998). Several antimalarial agents (such as chloroquine, quinine, pyrimethamine, cycloguanil, sulphadoxine and others) have lost their effectiveness against this disease through drug resistance being developed by the malarial parasites (The- Wellcome-Trust, 1999). Although there is no hard-core evidence of drug resistance shown on the new antimalarial compounds (artemisinin and artesunate), induced resistant studies in animal models have demonstrated that the malarial parasites have capabilities to develop resistance to these compounds (Ittarat et al., 2003; Meshnick, 1998; Meshnick, 2002; Walker et al., 2000). Furthermore, a useful vaccine has yet to be developed due to the complicated life cycle of the malarial parasites (The- Wellcome-Trust, 1999). As such, the re-emergence of this deadly infectious disease has caused an urgent awareness to constantly look for novel targets and compounds. In this present study, Plasmodium falciparum (clone 3D7) was cultured in vitro in human red blood cells for extraction of total RNA which was later reverse transcribed into cDNA. The áI-, áII- and â-tubulin genes of the parasite were then successfully amplified and cloned into a bacterial protein expression vector, pGEX- 6P-1. The tubulin genes were then sequenced and analysed by comparison with previously published homologues. It was found that the sequenced gene of áItubulin was different at twelve bases, of which only six of these had resulted in changes in amino acid residues. áII- and â-tubulin genes demonstrated 100% sequence similarity with the published sequences of clone 3D7, but differences were observed between this clone and other strains (strains NF54 & 7G8) of â-tubulin. Nevertheless, the differences were minor in áI- and â-tubulins and there was greater than 99% homology. Subsequently, all three Plasmodium recombinant tubulin proteins were separately expressed and purified. Insoluble aggregates (inclusion bodies) of these recombinant tubulins were also refolded and have been tested positive for their structural characteristics in Western blot analysis. Both soluble and refolded recombinant tubulins of malaria were examined in a drugtubulin interaction study using sulfhydryl reactivity and fluorescence quenching techniques. Known tubulin inhibitors (colchicine, tubulozole-c and vinblastine) and novel synthetic compounds (CCWA-110, 239 and 443) were used as the drug compounds to determine the dynamics and kinetics of the interactions. In addition, mammalian tubulin was also used to determine the potential toxicity effects of these compounds. Similarities were observed with other published reports in the binding of colchicine with the recombinant tubulins, hence confirming proposed binding sites of this compound on the Plasmodium recombinant tubulins. Two synthetic compounds (CCWA-239 and 443) that have previously tested positive against P. falciparum in vitro were found to bind effectively with all three tubulin monomers, while displaying low binding interactions with the mammalian tubulin, thus indicating that these compounds have potential antimalarial activity. Therefore, this study has satisfied and fulfilled all the aims and hypotheses that have previously been stated.
APA, Harvard, Vancouver, ISO, and other styles
8

SHROFF, PURVI B. "AN ASSESSMENT OF THE POTENTIAL INFLUENCE OF BEXAROTENE, A NOVEL RETINOID X RECEPTOR AGONIST, ON THE HEPATIC METABOLISM OF BEXAROTENE." University of Cincinnati / OhioLINK, 2005. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1123813553.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Martínez-Jiménez, Francisco 1988. "Structural study of the therapeutic potential of protein-ligand interactions." Doctoral thesis, Universitat Pompeu Fabra, 2016. http://hdl.handle.net/10803/565402.

Full text
Abstract:
Most of the cellular functions are driven by small-molecules that selectively bind to their protein targets. Is such their importance, that the pharmacological intervention of proteins by small molecule drugs is frequently used to treat multiple conditions. Herein I present a thesis that leverages a threedimensional study of small molecule protein interactions to improve their therapeutic relevance. More specifically, it introduces nAnnolyze, a method for predicting structurally detailed protein-ligand interactions at proteome scale. The method exemplified its applicability by predicting the human targets of all small molecule FDA-approved drugs. A second application of nAnnolyze in Mycobacterium tuberculosis identified the bacterial targets for two sets of compounds with known antitubercular activity. Finally, the thesis describes a computational model that predicts cancer associated mutations with the highest chances to confer resistance to a targeted cancer therapy. Additionally, for those mutations identified as responsible of resistance, the model also suggested alternative non-resistant treatments.<br>La mayor´ıa de las funciones celulares est´an dirigidas por peque˜nas mol´eculas que selectivamente se unen a sus prote´ınas diana. Es tal su importancia que la intervenci´on farmacol´ogica de prote´ınas mediante peque˜nas mol´eculas es frecuentemente usada para tratar m´ultiples enfermedades. A continuaci´on presento a una tesis que utiliza un estudio tridimensional de las interacciones entre peque˜nas mol´eculas y prote´ınas para mejorar su relevancia terap´eutica. Espec´ıficamente, presento nAnnolyze, un m´etodo que predice interacciones prote´ına-ligando estructuralmente detalladas y a nivel de proteoma. El m´etodo ejemplifica su aplicabilidad a trav´es de la predicci´on de dianas terap´euticas humanas para todas las peque˜nas mol´eculas usadas como f´armacos aprobados por la FDA. Una segunda aplicaci´on de nAnnolyze en Mycobacterium tuberculosis identific´o las prote´ınas diana para dos conjuntos de compuestos con actividad contra dicha bacteria. Finalmente, la tesis describe un modelo computacional que predice mutaciones asociadas a c´ancer con alta probabilidad de conferir resistencia a una terapia dirigida. Adem´as, para aquellas mutaciones identificadas como responsables de producir resistencia, el modelo tambi´en sugiere terapias alternativas predichas como no resistentes. III
APA, Harvard, Vancouver, ISO, and other styles
10

Bossaer, John B. "Addressing Potential Interactions Between Antineoplastics and Dietary Supplements." Digital Commons @ East Tennessee State University, 2015. https://doi.org/10.2146/ajhp140295.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Potential Drug – Drug Interactions"

1

Huang, L. Evaluation of the potential pharmacokinetic interaction between naproxen and zidovudine. Ottawa General Hospital, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

David, Rodrigues A., ed. Drug-drug interactions. M. Dekker, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

David, Rodrigues A., ed. Drug-drug interactions. 2nd ed. Informa Healthcare, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

David, Rodrigues A., ed. Drug-drug interactions. 2nd ed. Informa Healthcare, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

R, Horn John, and Hansten Philip D, eds. Drug interactions: Clinical significance of drug-drug interactions. 6th ed. Lea & Febiger, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Corporation, Springhouse, ed. Drug interactions. Springhouse Corp., 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

S, Tatro David, ed. Drug interactions. Facts & Comparisons, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pai, Manjunath P., Jennifer J. Kiser, Paul O. Gubbins, and Keith A. Rodvold, eds. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-72416-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Albert P., ed. Drug–Drug Interactions in Pharmaceutical Development. John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470187920.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

P, Li A., ed. Drug-drug interactions in pharmaceutical development. Wiley-interscience, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Potential Drug – Drug Interactions"

1

Kelleci Celik, Feyza. "Antidiabetic Drug Interactions." In Current Perspective on Diabetes Mellitus in Clinical Sciences. Nobel Tip Kitabevleri, 2023. http://dx.doi.org/10.69860/nobel.9786053359111.4.

Full text
Abstract:
Antidiabetic drug interactions pose significant challenges in the management of diabetes mellitus. These interactions can occur between different classes of antidiabetic medications or between antidiabetic drugs and other medications used to treat comorbid conditions. They may affect drug efficacy or safety by altering drug metabolism, absorption, or excretion. Common interactions include sulfonylureas, which can potentiate hypoglycemia when combined with other drugs that affect glucose levels. Similarly, medications such as corticosteroids or certain antibiotics can impair glucose control in diabetic patients. Clinicians must carefully monitor and adjust medication regimens to minimize these interactions and optimize therapeutic outcomes for patients with diabetes.
APA, Harvard, Vancouver, ISO, and other styles
2

Bauters, Tiene, and Adrin Dadkhah. "Clinically Relevant Drug Interactions in HCT." In The EBMT Handbook. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_31.

Full text
Abstract:
AbstractPatients undergoing HCT receive polymedication which carries the potential to result in drug interactions. To avoid unexpected outcomes, attention to drug interactions is crucial, especially when drugs with a narrow therapeutic index or inherent toxicity profile are involved.
APA, Harvard, Vancouver, ISO, and other styles
3

Khoo, Saye, Fiona Marra, and Alison Boyle. "Available Agents: Contraindications and Potential Drug–Drug Interactions." In Hepatitis C: Care and Treatment. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-67762-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Vázquez, Marta, Carlos García-Carnelli, Cecilia Maldonado, and Pietro Fagiolino. "Clinical Pharmacokinetics of Cannabinoids and Potential Drug-Drug Interactions." In Advances in Experimental Medicine and Biology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-61663-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Weinberg, Mea A., and Stuart J. Froum. "How to Manage Potential Drug Interactions." In The Dentist's Drug and Prescription Guide. John Wiley & Sons, Inc.,, 2013. http://dx.doi.org/10.1002/9781118704721.ch5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Joy, Christy, and Marria C. Cyriac. "Phytochemicals as Potential Drug Candidates for SARS Cov-2: An RDRp Based In-Silico Drug Designing." In Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022). Atlantis Press International BV, 2022. http://dx.doi.org/10.2991/978-94-6463-020-6_7.

Full text
Abstract:
AbstractThe global pandemic that the world is currently witnessing, COVID-19, even with vaccines available, the test positivity rate (TPR) tends to remain highly threatening. This research focuses on identifying phytochemicals, previously known for their broad-spectrum antiviral properties which can be potential drug candidates for theSARS-CoV-2. A total of 225 phytocompounds (downloaded from PubChem database) are docked against targetprotein (downloaded from PDB database) of SARS-CoV-2using the POAP pipeline. The target protein is the RDRp complex. They are screened according to their binding affinity values and the filtered phytochemicals are then subjected to various analyses including ADME properties (preADMET, swissADME), bioactivity score, and molecular properties (molinspiration), drug-likeness (preADMET), lipophilicity, water solubility, and pharmacokinetics (swissADME). The receptor-ligand interactions and the amino acid positions are obtained using Discovery Studio Visualiser. Molecular dynamic simulation studies are performed to reveal key receptor-drug interactions that must be formed to achieve tight drug binding and also to predict stability. Out of the 225, 10 phytochemicals showed the best scores and more probability of drug action. Compounds that showed promising drug action potential include oriciacridone, corilagin, cinchophyllamine, sophaline D, amentoflavone, cryptomisrine, ginkgetin, hypericin, pseudojervine, dieckol, hinokiflavone, robustaflavone, solamargine. The research herein provides new possibilities for in vitro and in vivo analyses of the proposed ligands to develop new drugs againstSARS-CoV-2.
APA, Harvard, Vancouver, ISO, and other styles
7

Coales, Una F. "Theme: Causes of potential drug toxicity through drug interaction." In PLAB: 1000 Extended Matching Questions. CRC Press, 2024. http://dx.doi.org/10.1201/9781003579687-72.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Jibin, Qing Wang, and Ismael J. Hidalgo. "In Vitro Methodologies to Assess Potential for Transporter-Mediated Drug–Drug Interactions." In Methods in Pharmacology and Toxicology. Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1250-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Poon, Anne, and Lowan K. Ly. "Common Potential Drug Interactions Following Hematopoietic Cell Transplantation." In Thomas’ Hematopoietic Cell Transplantation. John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118416426.ch98.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tidd, David M. "Antisense Oligonucleotides as Potential Inhibitors of Gene Expression." In Molecular Aspects of Anticancer Drug-DNA Interactions. Macmillan Education UK, 1993. http://dx.doi.org/10.1007/978-1-349-12356-8_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Potential Drug – Drug Interactions"

1

Fuadi, Mukhlish, Adhi Dharma Wibawa, Edwin Nugroho Njoto, and Ghulam Asrofi Buntoro. "Identification of Potential Drug-Drug Interactions Using EMR Text-Mining on Atherosclerotic Heart Disease Patients." In 2024 IEEE International Conference on Industry 4.0, Artificial Intelligence, and Communications Technology (IAICT). IEEE, 2024. http://dx.doi.org/10.1109/iaict62357.2024.10617451.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Liu, Ang, Yafang Huang, Yuehong Wu, Siwei Liu, and Shangsong Liang. "Active Learning for Multi-Class Drug-Drug Interactions Prediction." In 2024 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2024. https://doi.org/10.1109/bibm62325.2024.10822197.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yu, W., R. Rajagopalan, J. Lin, and P. Ibrahim. "Preclinical Evaluation of Cudetaxestat for Potential Drug-Drug Interactions." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2719.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Peric, A., and S. Vezmar Kovacevic. "4CPS-128 Potential drug-drug interactions in hypertensive patients." In 28th EAHP Congress, Bordeaux, France, 20-21-22 March 2024. British Medical Journal Publishing Group, 2024. http://dx.doi.org/10.1136/ejhpharm-2024-eahp.232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pomares Bernabeu, M., G. Miralles Andreu, S. Martinez Perez, A. Garcia Monsalve, C. Matoses Chirivella, and A. Navarro Ruiz. "4CPS-094 Characterisation of potential drug–drug interactions in oncological patients treated with oral anticancer drugs." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.195.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Faizah, Ana Khusnul, and Nani Wijayanti Dyah Nurrahman. "Evaluation of Potential Drug-Drug Interactions in Hypercholesterolemia Patients at Teaching Hospital Surabaya." In 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020). Atlantis Press, 2021. http://dx.doi.org/10.2991/ahsr.k.210115.064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rollins, K., K. Laliberte, K. Gotzkowsky, M. Wade, and D. Mottola. "Overview of the Drug-Drug Interaction Potential with Treprostinil." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3367.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mody, D., W. Yu, J. Lin, and P. Ibrahim. "Clinical Evaluation of Cudetaxestat for Safety,Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Drug-Drug Interactions." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2438.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Baniasadi, Shadi, Maryam Hassanzad, and Maryam Alehashem. "Potential drug-drug interactions in the pediatric intensive care unit of a pulmonary teaching hospital." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Amengual, Jennifer E., Gary K. Schwartz, Lora Inclan, et al. "Abstract CT028: Drug-drug interaction potential of EZH2 inhibitor tazemetostat (TAZ)." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-ct028.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Potential Drug – Drug Interactions"

1

Matthews, Lisa, Guanming Wu, Robin Haw, et al. Illuminating Dark Proteins using Reactome Pathways. Reactome, 2022. http://dx.doi.org/10.3180/poster/20221027matthews.

Full text
Abstract:
Diseases are often the consequence of proteins or protein complexes that are non-functional or that function improperly. An active area of research has focused on the identification of molecules that can interact with defective proteins and restore their function. While 22% percent of human proteins are estimated to be druggable, less than fifteen percent are targeted by FDA-approved drugs, and the vast majority of untargeted proteins are understudied or so-called "dark" proteins. Elucidation of the function of these dark proteins, particularly those in commonly drug-targeted protein families, may offer therapeutic opportunities for many diseases. Reactome is the most comprehensive, open-access pathway knowledgebase covering 2585 pathways and including 14246 reactions, 11088 proteins, 13984 complexes, and 1093 drugs. Placing dark proteins in the context of Reactome pathways provides a framework of reference for these proteins facilitating the generation of hypotheses for experimental biologists to develop targeted experiments, unravel the potential functions of these proteins, and then design drugs to manipulate them. To this end, we have trained a random forest with 106 protein/gene pairwise features collected from multiple resources to predict functional interactions between dark proteins and proteins annotated in Reactome and then developed three scores to measure the interactions between dark proteins and Reactome pathways based on enrichment analysis and fuzzy logic simulations. Literature evidence via manual checking and systematic NLP-based analysis support predicted interacting pathways for dark proteins. To visualize dark proteins in the context of Reactome pathways, we have also developed a new website, idg.reactome.org, by extending the Reactome web application with new features illustrating these proteins together with tissue-specific protein and gene expression levels and drug interactions.
APA, Harvard, Vancouver, ISO, and other styles
2

Committee on Toxicology. COT FSA PBPK for Regulators Workshop Report 2021. Food Standards Agency, 2024. http://dx.doi.org/10.46756/sci.fsa.tyy821.

Full text
Abstract:
The future of food safety assessment in the UK depends on the Food Standards Agency’s (FSA) adaptability and flexibility in responding to and adopting the accelerating developments in science and technology. The Tox21 approach is an example of one recent advancement in the development of alternative toxicity testing approaches and computer modelling strategies for the evaluation of hazard and exposure (New Approach Methodologies (NAMs). A key aspect is the ability to link active concentrations in vitro to likely concentrations in vivo, for which physiologically based pharmacokinetic (PBPK) modelling is ideally suited. The UK FSA and the Committee on Toxicity of Chemicals in Food, Consumer Products, and the Environment (COT) held an “PBPK for Regulators” workshop with multidisciplinary participation, involving delegates from regulatory agencies, government bodies, academics, and industry. The workshop provided a platform to enable expert discussions on the application of PBPK to health risk assessment in a regulatory context. Presentations covered current application of PBPK modelling in the agrochemical industry for in vitro to in vivo extrapolation (IVIVE), pharmaceutical industry for drug absorption related issues (e.g., the effect of food on drug absorption) and drug-drug interaction studies, as well as dose extrapolations to special populations (e.g., those with a specific disease state, paediatric/geriatric age groups, and different ethnicities), environmental chemical risk assessment, an overview of the current regulatory guidance and a PBPK model run-through. This enabled attendees to consider the wide potential and fitness for purpose of the application of PBPK modelling in these fields. Attendees considered applicability in the context of future food safety assessment for refining exposure assessments of chemicals with narrow margins of exposure and/or to fill data gaps from more traditional approaches (i.e., data from animal testing). The overall conclusions from the workshop were as follows: PBPK modelling tools were applicable in the areas of use covered, and that expertise was available (though it is in small numbers). PBPK modelling offers opportunities to address questions for compounds that are otherwise not possible (e.g., considerations of human variability in kinetics) and allows identification of “at risk” subpopulations. The use of PBPK modelling tends to be applied on a case-by-case basis and there appears to be a barrier to widespread acceptance amongst regulatory bodies due to the lack of available in-house expertise (apart from some medical and environmental agencies such as the European Medicines Agency, United States Food and Drug Administration, and the US Environmental Protection Agency, respectively). Familiarisation and further training opportunities on the application of PBPK modelling using real world case studies would help in generating interest and developing more experts in the field, as well as furthering acceptance. In a regulatory context, establishing fitness for purpose for the use of PBPK models requires transparent discussion between regulatory agencies, government bodies, academics, and industry and the development of a harmonised guidance such as by the Organisation for Economic Co-operation and Development (OECD) would provide a starting point. Finally, PBPK modelling is part of the wider “new approach methodologies” for risk assessment, and there should be particular emphasis in modelling both toxicodynamics and toxicokinetics.
APA, Harvard, Vancouver, ISO, and other styles
3

Basu, Sayani. Pharmacognosy in Drug Development. Spring Library, 2021. http://dx.doi.org/10.47496/nl.blog.23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Phillips, Sara, ed. The untapped potential of effective non-drug treatments. Monash University, 2021. http://dx.doi.org/10.54377/41a1-0317.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Phillips, Sara, ed. The untapped potential of effective non-drug treatments. Monash University, 2022. http://dx.doi.org/10.54377/98db-ce9f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cahaner, Avigdor, Susan J. Lamont, E. Dan Heller, and Jossi Hillel. Molecular Genetic Dissection of Complex Immunocompetence Traits in Broilers. United States Department of Agriculture, 2003. http://dx.doi.org/10.32747/2003.7586461.bard.

Full text
Abstract:
Objectives: (1) Evaluate Immunocompetence-OTL-containing Chromosomal Regions (ICRs), marked by microsatellites or candidate genes, for magnitude of direct effect and for contribution to relationships among multiple immunocompetence, disease-resistance, and growth traits, in order to estimate epistatic and pleiotropic effects and to predict the potential breeding applications of such markers. (2) Evaluate the interaction of the ICRs with genetic backgrounds from multiple sources and of multiple levels of genetic variation, in order to predict the general applicability of molecular genetic markers across widely varied populations. Background: Diseases cause substantial economic losses to animal producers. Emerging pathogens, vaccine failures and intense management systems increase the impact of diseases on animal production. Moreover, zoonotic pathogens are a threat to human food safety when microbiological contamination of animal products occurs. Consumers are increasingly concerned about drug residues and antibiotic- resistant pathogens derived from animal products. The project used contemporary scientific technologies to investigate the genetics of chicken resistance to infectious disease. Genetic enhancement of the innate resistance of chicken populations provides a sustainable and ecologically sound approach to reduce microbial loads in agricultural populations. In turn, animals will be produced more efficiently with less need for drug treatment and will pose less of a potential food-safety hazard. Major achievements, conclusions and implications:. The PI and co-PIs had developed a refined research plan, aiming at the original but more focused objectives, that could be well-accomplished with the reduced awarded support. The successful conduct of that research over the past four years has yielded substantial new information about the genes and genetic markers that are associated with response to two important poultry pathogens, Salmonella enteritidis (SE) and Escherichia coli (EC), about variation of immunocompetence genes in poultry, about relationships of traits of immune response and production, and about interaction of genes with environment and with other genes and genetic background. The current BARD work has generated a base of knowledge and expertise regarding the genetic variation underlying the traits of immunocompetence and disease resistance. In addition, unique genetic resource populations of chickens have been established in the course of the current project, and they are essential for continued projects. The US laboratory has made considerable progress in studies of the genetics of resistance to SE. Microsatellite-marked chromosomal regions and several specific genes were linked to SE vaccine response or bacterial burden and the important phenomenon of gene interaction was identified in this system. In total, these studies demonstrate the role of genetics in SE response, the utility of the existing resource population, and the expertise of the research group in conducting such experiments. The Israeli laboratories had showed that the lines developed by selection for high or low level of antibody (Ab) response to EC differ similarly in Ab response to several other viral and bacterial pathogens, indicating the existence of a genetic control of general capacity of Ab response in young broilers. It was also found that the 10w-Ab line has developed, possibly via compensatory "natural" selection, higher cellular immune response. At the DNA levels, markers supposedly linked to immune response were identified, as well as SNP in the MHC, a candidate gene responsible for genetic differences in immunocompetence of chickens.
APA, Harvard, Vancouver, ISO, and other styles
7

Kumar, Aishani, Thendral Yalini, and Sunil Kumar C. Unlocking Cellular Control: The Promise of PROTACs in Disease Intervention. Science Reviews - Biology, 2024. http://dx.doi.org/10.57098/scirevs.biology.3.2.1.

Full text
Abstract:
The discovery of proteolysis-targeting chimeras (PROTACs) is among the most exciting and promising avenues in cancer therapy. These fascinating compounds signify a paradigm shift from traditional approaches to medication development, offering a new idea that leverages the complexities of biological mechanisms to accomplish highly focused degradation of particular proteins implicated in pathological processes. This novel strategy has the potential to address a number of drawbacks with conventional therapy techniques, such as the development of drug resistance and unexpected adverse effects resulting from interactions that are not intended. The fundamental attraction of PROTACs is their distinct mode of action, which is based on controlling the cell's own machinery for protein degradation. This orchestrated degradation translates to a substantial reduction in the levels of disease-driving proteins, often leading to the disruption of critical pathways involved in cancer growth and progression. The in-depth principles underlying PROTAC technology are thoroughly explored in this review study, which also provides insight into the complex chemical mechanisms that enable these chimeric molecules to specifically degrade certain proteins while leaving others intact. Showcasing the potential of PROTACs as a revolutionary force in targeted cancer therapy, and focusing on its application in prostate and breast cancer especially, the article draws from a comprehensive compilation of preclinical and clinical studies, advancements, and breakthroughs in the field. The methods used to create and refine PROTACs for various cancer types will be examined throughout the review, along with the subtleties of the ligand and linker choices that are crucial to their effectiveness and selectivity. The difficulties and possibilities of transferring this ground-breaking technology from the lab to clinical practice will also be thoroughly examined, with an emphasis on issues like bioavailability, administration strategies, and potential resistance mechanisms. Through the integration of perspectives from various studies, the objective is to present a thorough but succinct review of the state of ongoing PROTAC research, emphasizing both, noteworthy advancements and the important issues that still need to be resolved. In the end, our investigation into PROTACs aims to shed light on how they can change the face of cancer therapy by providing a preview of a day when targeted protein degradation of disease-causing proteins would lead the way in novel therapeutic approaches.
APA, Harvard, Vancouver, ISO, and other styles
8

Lawanprasert, Somsong, Chaiyo Chaichantipyuth, Supatra Srichairat, Nuansri Niwattisaiwong, and Laddawal Phivthong-ngam. Subchronic exposure of Pueraria mirifica in normal - and high cholesterol diet fed rats : influence on hepatic cytochrome P450, lipid profile and toxicity. Chulalongkorn University, 2004. https://doi.org/10.58837/chula.res.2004.28.

Full text
Abstract:
Pueraria mirifica airy shaw and suvatabandhu, know locally as Kwao Keur, is a plant in family Leguminosae. In this study, effects of P.mirifica on hepatic cytochrome P450 (CYP), serum lipid profile and subchronic toxicity were investigated in male Wistar rats. Rats were randomly divided into four treatment groups as following: normal diet-fed group; normal diet-fed supplemented with P.mirifica group; high cholesterol diet-fed group; high cholesterol diet-fed supplemented with P.mirifica group. Each group comprised 10 rats. P.mirifica was administered orally at a dosage of 100 mg/kg/day for 90 consecutive days. At the end of the treatment, animals were anesthesized. Blood samples were collected by heart puncture and serum sample were prepared for determination of hematology and clinical blood chemistry, respectively. Microsomes were prepared from livers for enzyme assays. The results showed that body weight of rats given P.mirifica in either normal diet or high cholesterol diet conditions were significantly lower than their corresponding control groups. There was no significant difference of these following hematology and clinical blood chemistry: hemoglobin, hemotocrit, WBC count, %differential WBC, platelet count, RBC morphology, glucose, BUN, SCr, total bilirubin, and direct bilirubin in all experimental groups. P.mirifica did not affect serum level of AST, ALT, and ALP in normal diet-fed condition. High cholesterol diet-fed condition caused a significant increase of AST, ALT, and ALP but P.mirifica attenuated these effects. P.mirifica significantly decreased serum total cholesterol and LDL-C in either normal diet-fed or high cholesterol diet-fed rats. Serum triglyceride was increased in normal diet-fed rats but decreased in high cholesterol diet-fed rats. P.mirifica caused a significant decrease of HDL-C in both normal and high cholesterol diet-fed rats whereas its improvement in the LDL-C/HDL-C ratio was shown only in high cholesterol diet-fed rats. Concerning the effects on CYPs, P.mirifica significantly inhibited CYP2B1&amp;B2 in either normal diet or high cholesterol diet-fed rats. Its inhibitory effect of CYP1A2 and CYP2E1 was found only in normal diet-fed rats. No effect of P.mirifica was found on CYP1A1 and CYP3A. Inhibitory effects of P.mirifica on CYP2B1&amp;2B2 and CYP2E1 were also found in the in vitro study. Although, P.mirifica demonstrated a benefit on lipid profile and did not show any toxic effects on liver, kidney, and blood system in this study, an increment of serum triglyceride in normal rat receiving P.mirifica, howerer, is not favorable. Inhibitory effects of P.mirifica on CYP1A2, CYP2B1&amp;2B2 and CYP2E1 indicated a beneficial potential of this plant regarding the chemical-induced carcinogenesis as well as a possible potential of this plant regarding drug-drug interaction with other medicines that are metabolized by these CYPs. Effects of P.mirifica at various doses, long term used as well as mechanism of effects should be further investigated. Effects of P.mirifica on other isoforms of CYP in human should also be explored.
APA, Harvard, Vancouver, ISO, and other styles
9

Deehan, Clare, and Shaun McMahon. Remimazolam. A New Drug With Potential Applications in Anaesthesia and Critical Care. World Federation of Societies of Anaesthesiologists, 2025. https://doi.org/10.28923/atotw.543.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vera, Jose, and Ken Evans. PR186-203600-Z01 Impact of Drag Reducing Agents on Corrosion Management. Pipeline Research Council International, Inc. (PRCI), 2021. http://dx.doi.org/10.55274/r0012177.

Full text
Abstract:
The purpose of this research was to understand the potential impact of drag reducing agents (DRA) on internal corrosion of liquid hydrocarbon pipelines. The first task of this project included a comprehensive review of literature and knowledge, both in public domain and from industry experience, on the effect of DRA on water and solid transport in liquid hydrocarbons, and possible interactions with other performance chemicals typically used in the oil and gas industry. This was the basis for defining the final bench test methodology and test matrix to be performed in the second task. A novel bench-top apparatus was designed based on a vertical Couette cell approach, and a test methodology was successfully implemented to evaluate the potential effect(s) of DRA on water accumulation and localized corrosion at the oil/water interface. A test matrix was conducted with two DRAs (a water based and an oil based) and two corrosion inhibitors (a water soluble and an oil soluble) at a given test condition (3.5% NaCl saturated with 97%CO2/3%O2, pH ~6 at 80 oF). There is a related webinar.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Potential Drug – Drug Interactions' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography